ERBB2 and breast carcinoma: In the past years, a number of biomolecules against various targets have been investigated for radionuclide molecular imaging of breast cancer, such as somatostatin (SST) analogues targeting SST receptors, vasoactive intestinal peptide targeting affibody molecules against HER2, arginine-glycine-aspartate (RGD) peptides targeting integrin receptors, bombesin analogues targeting gastrin-releasing peptide receptors (GRPRs), and peptide analogues of alpha-melanocyte stimulating hormone-targeting melanocortin receptors [16].